Background: Autoimmune lymphoproliferative syndrome (ALPS) is a primary immunodeficiency characterized by chronic lymphoproliferation, autoimmune manifestations, expansion of double-negative T-cells, and susceptibility to malignancies. Most cases of ALPS are caused by germline or somatic FAS mutations. We report the case of an ALPS patient due to a novel homozygous Fasligand gene mutation (ALPS-FASLG). Methods: ALPS biomarkers were measured and FASLG mutation was identified. Functional characterization was carried out based on activation-induced cell death (AICD) and cytotoxicity assays. results: This report describes the cases of a patient who presented a severe form of ALPS-FASLG, and his brother who had died due to complications related to ALPS. Moreover, in another family, we present the first case of lymphoma in a patient with ALPS-FASLG. Functional studies showed defective Fasligand-mediated apoptosis, cytotoxicity, and AICD in T-cell blasts. Otherwise, expression of the FASLG gene and corresponding protein was normal, but the shedding of the Fasligand was impaired in T-cells. Additionally, analyzing Epstein-Barr virus (EBV)-transformed B-cells, our results indicate impaired AICD in ALPS-FASLG patients. conclusion: Patients with autosomal recessive inheritance of ALPS-FASLG have a severe phenotype and a partial defect in AICD in T-and B-cell lines. The Fasligand could play a key role in immune surveillance preventing malignancy. c linically, patients with autoimmune lymphoproliferative syndrome (ALPS) have nonmalignant lymphadenopathies, splenomegaly, autoimmune cytopenias, and susceptibility to malignancy (1-5). Immunological features of ALPS consist of an expanded population of double-negative (DN) T-cells (TcRαβ+CD4-CD8-), while elevated levels of circulating plasma biomarkers, including IL-10, IL-18, soluble Fas ligand (sFasL), and vitamin B12, have also been described (6,7). ALPS patients are classified according to the underlying genetic defect (Mendelian inheritance in man (MIM) no. 601859). Most cases of ALPS are associated with germline (ALPS-FAS) or somatic (ALPS-sFAS) heterozygous FAS mutations or a combination of both (3, 8, 9) . Mutations in the Fas ligand gene (FASLG) in ALPS (ALPS-FASLG) have only been reported in five patients, two of them with the autosomal dominant form (10,11) and three with the autosomal recessive form of the disease (12) (13) (14) . Cases with clinical and immunological features of ALPS with unknown genetic defects are referred to as ALPS-U (15). In addition, the demonstration of an apoptosis defect is critical for the diagnosis of ALPS. Specifically, activation-induced cell death (AICD), a homeostatic mechanism involved in the termination of the adaptive immune response by extrinsic or intrinsic cell death pathways, is impaired in ALPS-FASLG patients (12,13,16) (see Supplementary Table  S1 online).
c linically, patients with autoimmune lymphoproliferative syndrome (ALPS) have nonmalignant lymphadenopathies, splenomegaly, autoimmune cytopenias, and susceptibility to malignancy (1) (2) (3) (4) (5) . Immunological features of ALPS consist of an expanded population of double-negative (DN) T-cells (TcRαβ+CD4-CD8-), while elevated levels of circulating plasma biomarkers, including IL-10, IL-18, soluble Fas ligand (sFasL), and vitamin B12, have also been described (6, 7) . ALPS patients are classified according to the underlying genetic defect (Mendelian inheritance in man (MIM) no. 601859). Most cases of ALPS are associated with germline (ALPS-FAS) or somatic (ALPS-sFAS) heterozygous FAS mutations or a combination of both (3, 8, 9) . Mutations in the Fas ligand gene (FASLG) in ALPS (ALPS-FASLG) have only been reported in five patients, two of them with the autosomal dominant form (10, 11) and three with the autosomal recessive form of the disease (12) (13) (14) . Cases with clinical and immunological features of ALPS with unknown genetic defects are referred to as ALPS-U (15) . In addition, the demonstration of an apoptosis defect is critical for the diagnosis of ALPS. Specifically, activation-induced cell death (AICD), a homeostatic mechanism involved in the termination of the adaptive immune response by extrinsic or intrinsic cell death pathways, is impaired in ALPS-FASLG patients (12, 13, 16 ) (see Supplementary Table  S1 online).
This report describes the cases of two Moroccan brothers (P1 and P2), born to consanguineous parents, who presented a severe form of ALPS caused by a novel homozygous FASLG mutation. Given that alterations in immune tolerance have been described in ALPS patients (3), we decided to assess the impact of Fas ligand (FasL) deficiency on cytotoxicity and apoptosis both in T-cell blasts and B-cell lines transformed with EpsteinBarr virus (EBV). These results are compared with those of a patient with FasL deficiency (P3) who, since previously being described by our group (12) , has had a lymphoma.
RESULTS

Clinical, Immunologic, and Molecular Features of ALPS-FASLG Patients
At the age of 8 mo, P1 was admitted to hospital for persistent generalized lymphadenopathy and hepatosplenomegaly, thrombocytopenia and anemia, accompanied by intermittent fever and diarrhea. He also had upper respiratory tract infections, bronchiolitis, and pneumonia. The most prominent immunological abnormalities in P1 included increased percentage and number of DN T-cells, high plasma IL-10, vitamin B12 and sCD25 levels, and hypergammaglobulinemia. However, sFasL was not detected, unlike in ALPS-FAS patients ( Table 1) . Mutations in the FAS gene were also ruled out in this patient. At this stage, ALPS-FASLG was suspected.
FASLG sequencing analysis revealed a novel homozygous G-to-C substitution at cDNA nucleotide 605 (GenBank KJ948655), which produces a nonconservative mutation C202S in exon 4 affecting the extracellular domain of the protein. The mutation was confirmed in cDNA and genomic DNA. This mutation was not found as a single nucleotide polymorphism and was absent in 100 healthy donors. We found that codon 202 is conserved in 10 species other than humans, which underlines the importance of this amino acid for proper functioning of the protein (see Supplementary Figure S1a online). Both parents and one sibling are heterozygous carriers, and they are healthy without any clinical evidence or history of ALPS (see Supplementary Figure S1b online). The patient was treated with corticosteroids and rapamycin, and this led to a remarkable and rapid reduction of the size of his spleen, liver, and lymph nodes. Lower numbers of DN T cells, normal levels of immunoglobulins, negative antinuclear antibodies, and normal platelet counts were observed after starting the treatment. He recovered from CMV pneumonitis with treatment with valganciclovir. Mild pulmonary toxicity secondary to rapamycin was suspected, and resolved after decreasing the daily dose.
His sibling, P2, previously died at 3 y of age with dramatic failure to thrive, massive hepatosplenomegaly, respiratory insufficiency, pancytopenia, and increased levels of ferritin, vitamin B12 and immunoglobulins. The FASLG mutation in this patient (C202S) was confirmed in genomic DNA from a postmortem sample (see Supplementary Figure S1b online).
P3 is an ALPS-FASLG patient, followed-up clinically for more than 19 y (12), who developed lymphoma. She complained of a 3-wk period of flu-like illness accompanied by asthenia and dizziness. On physical examination, splenomegaly was noted (8 cm below left costal margin). Blood tests were normal. Abdominal ultrasound revealed spleen enlargement (15 cm) and a heterogeneous retroperitoneal mass (18 × 7 × 8 cm) with a cystic component on its lower edge, located between left psoas muscle and ipsilateral kidney. Whole-body CT showed scattered axillary and upper mediastinal lymphadenopathies (all less than 1 cm in diameter), and abdominal lymphadenopathies located in the peripancreatic mesentery. Dimensions of the abdominal (solid and slightly hypodense) mass were 16 × 11 × 10 cm (see Supplementary Figure S2 . Further, 40% of the blasts were positive for Ki-67. This was consistent with a diagnosis of peripheral T-cell lymphoma. She was treated with the standard chemotherapy regimen for non-Hodgkin lymphoma (CHOP), and has been asymptomatic for the last 8 y without disease flares. At the time of writing, this patient is pregnant and has no apparent lymphoproliferative or autoimmune phenomena. We conclude that, as in ALPS-FAS patients, clinical follow-up in ALPS-FASLG patients is warranted due to the risk of malignant lymphoproliferative disorders.
Impaired FasL-Mediated Cytotoxicity
To explore whether the FasL in P1 had lost its cytotoxic activity, cytotoxicity assays were performed using phytohemagglutinin (PHA)-activated T-cell blasts from P1, P3, and two healthy controls. T-cell blasts from P1 (like those from P3) caused less cytolysis of Jurkat cells than T-cell blasts from controls, suggesting that the FasL from P1 was inactive (Figure 1a) .
To explore FasL functional activity in P1, full-length cDNA alleles (FASLG wild-type from a healthy control and mutant Articles from P1) were cloned into the pIRES2dsRED2 expression vector. These clones were then transfected into the effector cells (H293T) and cytotoxicity assays were performed using L1210. Fas and L1210 cells as targets. As shown by 7-AAD staining, H293T cells transfected with wild-type FASLG clearly induce death of L1210.Fas cells. In contrast, H293T cells transfected with mutant FASLG did not induce death in L1210.Fas target cells at effector:target (E:T) ratios of 1:1, 5:1, or 10:1. As a control, it was confirmed that no significant cytotoxicity was observed in Fas-negative L1210 cells under the same conditions (Figure 1b) . Additionally, the cytotoxic activity of FasL released on exosomes in H293T-transfected cells was measured in the supernatants using L1210.Fas cells as targets and L1210 cells as a negative control. Results showed that supernatants from the wild-type FASLG H293T-transfected cells induced a higher rate of death in L1210.Fas cells than supernatants from the mutant FASLG cells (Figure 1c) .
FasL Expression Analysis
To rule out that the defective Fas-mediated cytotoxicity in T-cell blasts from P1 was caused by a low level of FasL expression, we analyzed expression of the FASLG gene and corresponding protein. The mRNA expression level, measured by RT-PCR analysis, was similar in P1 and in healthy controls, indicating that the FASLG mutation did not abrogate normal processing of the gene (Figure 2a) . Additionally, the FasL protein was clearly detected in P1 T-cell blasts by western blot and the level of the protein was comparable to that in healthy controls (Figure 2b) . Immunophenotypic analysis of both surface and cytoplasmic FasL expression of CD4 + and CD8 + T cells found comparable levels in P1, P3, and the healthy controls (data not shown). However, sFasL was not detectable in either plasma or cell supernatants of activated peripheral blood mononucleated cells (anti-CD3+anti-CD28 and PHA) from P1 and P3, unlike in those from healthy controls. These results indicate that the FASLG mutation in these patients inhibited the shedding of the sFasL protein (Figure 2c ).
Decreased Activation-Induced Cell Death
The Fas/FasL pathway was evaluated using functional apoptosis assays. T-cell blasts from P1 showed normal Fas-mediated apoptosis when it was induced by an agonistic anti-Fas antibody (Apo1.3) (Figure 3a) . However, we observed a partial reduction in AICD in T-cell blasts from P1 at all doses of PHA. T-cell blasts from a Fas-deficient patient (ALPS-FAS) were also used, and these showed impaired Fas-mediated apoptosis and conserved AICD. The AICD results in P1 were comparable with those previously observed in ALPS-FASLG patients (12,13) (see Supplementary Table S1 online) (Figure 3b) . However, our study indicates for the first time impaired AICD in ALPS-FASLG patients (P1 and P3) using EBV-transformed B cells. We did not observe significant differences between the patients and controls in Fas-mediated apoptosis using Apo1.3, but when B-cell lines were re-stimulated with PHA or with ionomycin + PMA, a partial reduction in AICD was also observed in P1 and P3 (Figure 3c,d) . The expression of FasL was barely detectable in the EBV-transformed cell lines from the patients and controls (data not shown); however, the AICD defect was partial in ALPS-FASLG patients. These results could indicate that a Fas-FasL-independent pathway accounts for the partial cell death of FasL-deficient EBV-transformed cell lines from the patients, as has been previously described for FasLdeficient T-cells (results shown above and in refs. 12, 13 ). and P3 ) using PHA, ionomycin (Ion) + PMA and anti-Fas mAb (500 ng/ml). Columns show the mean ± SD of three independent experiments. Statistical comparisons were performed with unpaired Student's t-tests, with significance indicated by asterisks (*P < 0.05, **P < 0.01), and ns, no statistical significance. Figure S1b online). Fas/FasL-mediated cytotoxicity was severely impaired in P1, probably due to the mutation found in FASLG giving rise to a nonfunctional protein. Additionally, expression of the FASLG gene and corresponding protein was conserved, but sFasL was not be detected, suggesting that the FASLG mutation in these patients inhibits shedding of the sFasL protein (Figures 1 and 2) . The results confirm a partial reduction in AICD in both T-cell blasts and EBV-transformed B-cell lines (Figure 3) , demonstrating that the impact of the mutations on AICD is very similar and showing that other pathways are acting in AICD induction, as previously described in other ALPS-FASLG and ALPS-FAS patients (12, 13, 17, 18) . It is remarkable to observe this difference in AICD in EBV-transformed B-cell lines, given that the percentage of cells that express FasL is low (no more than 10%, data not shown) both in B-cells from the controls and from the patients. This could indicate that the main mechanism of Fas/FasL-mediated AICD in these cells, as observed previously by our group in human T-cell blasts (19) , is mediated by the release of FasL on the surface of exosomes, inducing not only the suicide of the same exosome-releasing cells, but also the fratricide of neighboring Fas-expressing cells.
It is likely that the differential impact of FAS and FASLG mutations on AICD is attributable to this type of cell death being conserved in heterozygous ALPS-FAS patients, while it is partially impaired in homozygous ALPS-FAS and ALPS-FASLG patients (12, 17, 18) . The complete absence of Fas signaling in the latter groups, patients with the homozygous forms of the syndrome, causes a defect in AICD that can be detected in vitro. However, in heterozygous ALPS-FAS patients, it seems that other Fas-independent mechanisms are playing a role in AICD and able compensate for the defect, no differences being detected in vitro.
One of these Fas-independent mechanisms could be the perforin/granzyme pathway, especially relevant for CD8 + T-cells, the role of this pathway to AICD becoming relatively more important in the absence of a contribution from the Fas/FasL pathway (17) . In spite of this possible partial compensation, the absence of Fas/FasL-mediated regulation results in severe disease, especially massive lymphoproliferation and an increased risk of lymphoma. In fact, we report here the development of a T-cell lymphoma by P3 (12, 18) . To our knowledge, this is the first reported case of lymphoma in a patient with ALPS-FASLG. The risk of Hodgkin's and non-Hodgkin's lymphomas in families with ALPS-FAS syndrome has been estimated to be respectively 149 times and 61 times greater than expected, with the majority of lymphomas being of B-cell lineage (89%) (5) .
In summary, we describe a new case of ALPS-FASLG with a severe clinical phenotype, in addition to alterations in cytotoxicity and apoptosis. Although FasL deficiency is rare, this case represents the sixth patient described and the fourth with autosomal recessive inheritance (see Supplementary  Table S1 online). Additionally, this study is the first to demonstrate defective AICD in EBV-transformed B-cells from ALPS-FASLG patients, results suggesting that the link between the partial defect in AICD in T-and B-cells in ALPS-FASLG patients and lymphoma merits further investigation.
METHODS
Patients
The study was approved by the clinical ethics committee of Hospital Universitario 12 de Octubre (Spain). Blood samples were obtained from the patients, their relatives, and healthy controls after they had given written informed consent in agreement with the principles of the Declaration of Helsinki.
ALPS Biomarkers
Proportions of DN T cells were determined in total blood samples by flow cytometry using a Navios Cytometer (Beckman Coulter, Madrid, Spain). Mouse anti-human monoclonal antibodies were used to identify this population: anti-TCRαβ-FITC, anti-TCRγδ-PE, anti-CD3-PerCP5.5 (BD Biosciences, Madrid, Spain), anti-CD8-PeCy7, anti-CD4-APC, and anti-CD45-APC-Alexa Fluor 750 (Beckman Coulter). Activated T-cells and B-cell phenotype were also tested in the ALPS-FASLG patient. Mouse anti-human monoclonal antibodies were used to identify these populations: anti-HLA-DR-PE, anti-CD3-PerCP5.5, anti-IgD-PE (BD Biosciences), anti-CD19-FITC, and anti-CD27-PC5 (Beckman Coulter).
Plasma levels of IL-10 (Bender MedSystems, LabClinics, Madrid, Spain), sCD25 and sFasL (R&D Systems, Vitro, Madrid, Spain) and vitamin B12 (Beckman Coulter) were measured in duplicate by enzyme-linked immunosorbent assay. Serum immunoglobulin levels (IgG, IgA, IgM) were measured by nephelometry (Beckman Coulter).
Cells and Cell Culture
Human peripheral-blood mononuclear cells were obtained from the blood of patients and healthy donors by Ficoll separation. T-cell blasts were generated from these cells by PHA stimulation (20 ng/ml) (SigmaAldrich, Madrid, Spain) in the presence of IL-2 (100 IU/ml) (Roche, Madrid, Spain), as described elsewhere (12) . EBV-transformed B-cell lines derived from patients and normal donors were maintained in RPMI 1640 with 20% fetal calf serum, 2 mmol/l L-glutamine, penicillin 100 U/ml and 100 μg/ml streptomycin (Sigma-Aldrich) at 37 °C in a humidified 5% CO 2 incubator. Jurkat cells (clone E6-1, derived from a T-cell acute leukemia, ATCCTIB-152) and HEK-293T cells (derived from a human embryonic kidney cell line, ATCCCRL-3216) were also used for cytotoxicity experiments.
Molecular Genetics
Mutation analysis of FAS and FASL genes was performed as described elsewhere (12) .
Cytotoxicity Assays
Carboxyfluorescein succinimidyl ester (CFSE) staining of Jurkat, L1210 and L1210.Fas cells allows us to gate target cells in flow cytometry analysis and quantify cell death using 7-aminoactinomycin D (7AAD) staining exclusively in the target cell population. For FasL-induced cytolysis, 6-d-old T-cell blasts from P1, P3, and two healthy controls were tested for toxicity to Jurkat cells. We used an effector:target ratio of 2:1 in an overnight cytotoxicity assay and the results represent the percentage of Jurkat CFSE+ (Life Technologies, Madrid, Spain) cells positive for 7AAD staining (Immunostep, Salamanca, Spain).
Constructs were created and transfection was performed as described elsewhere (12) . Control H293T cells, or H293T cells transfected with either the wild type or the mutant FasL constructs, were also used as effectors in cytotoxicity assays. Transfection efficiency, based on microscopic evaluation of DsRed2 expression, varied from 25 to 30%. No significant differences in transfection efficiency were found between the wild-type and the mutant construct. Cells were tested at different effector:target ratios against CFSE-stained Fas-transfected murine L1210 cells (L1210.Fas) or against CFSEuntransfected L1210 cells negative for Fas expression (L1210) in 6-h assays. The results represent the percentage of L1210.Fas-or L1210-CFSE+ cells positive for 7AAD staining.
Bioactive FasL is released to the supernatant by human cells in the form of whole, nonproteolyzed protein, associated with a particulate fraction characterized as exosomes that contain FasL on their surface (19) . Accordingly, supernatants from the cultures indicated above were collected and tested for toxicity on L1210.Fas and L1210. Cell death was measured using annexin V-FITC staining (Immunostep).
FASLG Expression
Total RNA was isolated from T-cell blasts with the RNeasy plus mini kit (Qiagen, Madrid, Spain). One microgram of total cellular RNA was reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit (Roche). Gene expression was analyzed by real-time PCR using a TaqMan Fast Universal PCR Master Mix and Taqman probes (FASLG: Hs00181225_m1) (Life Technologies) in accordance with the manufacturer's instruction. GADPH was used as the endogenous control, and the level of expression of FASLG was quantitatively measured relative to that in three different donors without the mutation.
Cell lysates (RIPA buffer, Sigma-Aldrich; protease inhibitor cocktail, Thermo Scientific, Madrid, Spain) were prepared from T-cell blasts. Cell lysates were resolved on 4 to 20% precast polyacrylamide gel (Biorad, Madrid, Spain). Proteins were blotted on a nitrocellulose membrane and probed with anti-FasL (Clone NOK-1, BD Biosciences) or anti-β-actin (Sigma-Aldrich) antibodies.
Peripheral-blood mononuclear cells (1 × 10 5 ) from P1, P3, and a healthy control were stimulated for 72 h with PHA (200 ng/ml) (SigmaAldrich), plate-bound anti-CD3 (10 μg/ml) and soluble anti-CD28 (2 μg/ml) (BD Biosciences) or left unstimulated. Supernatants were collected and sFasL levels were measured in duplicate by enzymelinked immunosorbent assay (R&D Systems, Vitro, Madrid, Spain).
To analyze FasL expression of T-cells and EBV-transformed B-cells, 1 × 10 5 cells were stained for FACS analysis with anti-human FasL-PE mAb (clone NOK-1; Miltenyi Biotec, Madrid, Spain) Apoptosis and AICD T-cell blasts (1 × 10 5 cells) from P1, P3, and healthy controls were cultured with different concentrations of anti-Fas mAb (125, 250, 500 ng/ ml) (Clon Apo1.3; Enzo Life Sciences, Madrid, Spain) and PHA (1.25, 2.5, and 5 μg/ml) (Sigma-Aldrich). After overnight incubation, apoptotic cells were detected by flow cytometry using annexin V-FITC.
EBV-transformed B-cells were aliquoted in triplicate into 96-well plates and cultured with PHA (5 μg/ml), ionomycin (1.25 μg/ml) plus phorbol-12-myristate-13-acetate (PMA, 100 ng/ml) (SigmaAldrich) and anti-Fas (Apo1.3, 500 ng/ml). After 16 h, apoptosis and loss of mitochondrial transmembrane potential were evaluated by flow cytometry using annexin V-FITC and DiOC2 staining (Life Technologies), respectively.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http:// www.nature.com/pr
